Sight Sciences (SGHT) director Donald Zurbay awarded 28,261 RSUs valued at about $130,000

Rhea-AI Filing Summary

Zurbay Donald reported acquisition or exercise transactions in this Form 4 filing.

Sight Sciences director Donald Zurbay received a grant of 28,261 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program. The award value is approximately $130,000, based on the closing price of the common stock on June 4, 2026.

The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, as long as Zurbay continues serving on the board through that date. After this grant, he has a total reported position of 193,613 shares and rights, including common shares, unvested RSUs, and stock options exercisable within 60 days.

Insights

Equity compensation analyst

Routine RSU grant to a director, expanding equity-based compensation without cash buying or selling.

The transaction is a grant of 28,261 RSUs to director Donald Zurbay, valued at about $130,000. This is compensation under the non-employee director program, not an open-market purchase, and is recorded at a per-unit price of $0.00 on the form.

The RSUs vest by the earlier of June 4, 2027 or the 2027 annual meeting, subject to continued board service, which encourages alignment over the coming year. Following the grant, Zurbay’s reported holdings total 193,613 shares and rights, combining common stock, unvested RSUs, and options exercisable within 60 days.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zurbay Donald

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	28,261	$0.00	--

Holdings After Transaction: Common Stock — 193,613 shares (Direct, null)

Footnotes (1)

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. Includes (i) 75,352 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 4, 2026.

Key Figures

RSU grant size: 28,261 RSUs RSU grant value: $130,000 Total holdings after grant: 193,613 shares/rights +3 more

6 metrics

RSU grant size 28,261 RSUs Non-Employee Director Compensation Program grant on June 4, 2026

RSU grant value $130,000 Approximate value based on closing price on June 4, 2026

Total holdings after grant 193,613 shares/rights Common stock, RSUs, and options after reported transaction

Common stock held 75,352 shares Common stock position included in post-transaction total

Exercisable stock options 90,000 shares Shares acquirable by option exercise within 60 days of June 4, 2026

Vesting date June 4, 2027 Latest vesting date; earlier if 2027 annual meeting occurs first

Key Terms

restricted stock units ("RSUs"), Non-Employee Director Compensation Program, stock options, par value $0.001 per share, +1 more

5 terms

restricted stock units ("RSUs") financial

"Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Non-Employee Director Compensation Program financial

"made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program"

stock options financial

"90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

par value $0.001 per share financial

"Issuer's common stock, par value $0.001 per share ("Common Stock")"

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zurbay Donald

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		28,261(1)	A	$0.00	193,613(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.

2. Includes (i) 75,352 shares of Common Stock, (ii) 28,261 RSUs which are subject to vesting as reported herein, and (iii) 90,000 shares of Common Stock which the Reporting Person has the right to acquire upon the exercise of stock options exercisable within 60 days of June 4, 2026.

	/s/Jeremy Hayden, Attorney-in-Fact for Donald Zurbay	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Sight Sciences (SGHT) director Donald Zurbay report in this Form 4?

Donald Zurbay reported receiving a grant of 28,261 restricted stock units from Sight Sciences. The RSUs were awarded under the company’s Non-Employee Director Compensation Program as equity compensation, with no cash paid per share in the reported transaction.

How much is Donald Zurbay’s RSU grant from Sight Sciences (SGHT) worth?

The RSU grant is valued at approximately $130,000 of Sight Sciences common stock. The company calculated this amount using the closing stock price on June 4, 2026, and then determined the number of RSUs so each unit represents one potential share.

When do Donald Zurbay’s Sight Sciences (SGHT) RSUs vest?

The RSUs vest on the earlier of June 4, 2027, or the date of Sight Sciences’ 2027 annual meeting. Vesting is conditioned on Zurbay’s continued service as a director on the company’s board of directors through the applicable vesting date.

How many Sight Sciences (SGHT) shares and rights does Donald Zurbay hold after this grant?

After the grant, Zurbay’s reported position totals 193,613 shares and rights. This includes 75,352 shares of common stock, 28,261 unvested RSUs from this award, and 90,000 shares he may acquire by exercising stock options within 60 days of June 4, 2026.

Is Donald Zurbay buying or selling Sight Sciences (SGHT) stock in this Form 4?

This Form 4 shows an equity award, not an open-market trade. Zurbay received 28,261 restricted stock units as director compensation, recorded at a zero cash price per unit, and there are no reported stock purchases or sales in the transaction data.